1.Lu L, Zeng H, Wan B, et al. Leukocyte telomere length and bipolar disorder risk: evidence from Mendelian randomization analysis[J]. PeerJ, 2023, 11: e15129. DOI: 10.7717/peerj.15129.
2.Osipova NN, Bardenshteyn LM, Beglyankin NI, et al. Early screening for risks of bipolar disorder at the preclinical stage[J]. Psychiatr Danub, 2021, 33(Suppl 4): 541-545. https://pubmed.ncbi.nlm.nih.gov/34718278/
3.Anmella G, Fico G, Lotfaliany M, et al. Risk of cancer in bipolar disorder and the potential role of lithium: international collaborative systematic review and Meta-analyses[J]. Neurosci Biobehav Rev, 2021, 126: 529-541. DOI: 10.1016/j.neubiorev.2021.03.034.
4.徐文斌, 龚乘丙, 李尧, 等. p53 codon 72 基因多态性与中国女性乳腺癌发生风险关系的系统评价与Meta分析[J]. 医学新知, 2022, 32(1): 23-32. [Xu WB, Gong CB, Li Y, et al. Association of p53 codon 72 polymorphism and breast cancer risk in Chinese women: a systematic review and Meta-analysis[J]. Yixue Xinzhi Zazhi, 2022, 32(1): 23-32.] DOI: 10.12173/j.issn. 1004-5511.202110001.
5.Carreira H, Williams R, Funston G, et al. Associations between breast cancer survivorship and adverse mental health outcomes: a matched population-based cohort study in the United Kingdom[J]. PLoS Med, 2021, 18(1): e1003504. DOI: 10.1371/journal.pmed. 1003504.
6.Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48. DOI: 10.3322/caac.21763.
7.Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
8.徐婷婷,杨若愚,李净净,等. 全球女性乳腺癌疾病负担社会经济影响因素分析[J]. 中国公共卫生, 2024, 40(11): 1375-1379. [Xu TT, Yang RY, Li JJ, et al. Socioeconomic indicators related to the global burden of breast cancer in women in 2020: an analysis of WHO data[J]. Chinese Journal of Public Health, 2024, 40(11): 1375-1379.] DOI: 10.11847lzggws1144500.
9.Anmella G, Fico G, Lotfaliany M, et al. Risk of cancer in bipolar disorder and the potential role of lithium: international collaborative systematic review and Meta-analyses[J]. Neurosci Biobehav Rev, 2021, 126: 529-541. DOI: 10.1016/j.neubiorev. 2021.03.034.
10.Peng H, Wu X, Ge F, et al. Genetically predicted bipolar disorder is causally associated with an increased risk of breast cancer: a two-sample Mendelian randomization analysis[J]. Ann Transl Med, 2021, 9(5): 401. DOI: 10.21037/atm-20-5372.
11.Han X, Lin X, Li G, et al. Association of cancer and schizophrenia, major depression and bipolar disorder: a Mendelian randomization study[J]. J Psychosom Res, 2024, 183: 111806. DOI: 10.1016/j.jpsychores.2024.111806.
12.Birney E. Mendelian randomization[J]. Cold Spring Harb Perspect Med, 2022, 12(4): a041302. DOI: 10.1101/cshperspect.a041302.
13.Kintu C, Soremekun O, Kamiza AB, et al. The causal effects of lipid traits on kidney function in Africans: bidirectional and multivariable Mendelian randomization study[J]. EBioMedicine, 2023, 90: 104537. DOI: 10.1016/j.ebiom.2023.104537.
14.Gala H, Tomlinson I. The use of Mendelian randomisation to identify causal cancer risk factors: promise and limitations[J]. J Pathol, 2020, 250(5): 541-554. DOI: 10.1002/path.5421.
15.Qiu R, Lin H, Jiang H, et al. Association of major depression, schizophrenia and bipolar disorder with thyroid cancer: a bidirectional two-sample Mendelian randomized study[J]. BMC Psychiatry, 2024, 24(1): 261. DOI: 10.1186/s12888-024-05682-7.
16.Shu X, Zhou Q, Sun X, et al. Associations between circulating proteins and risk of breast cancer by intrinsic subtypes: a Mendelian randomisation analysis[J]. Br J Cancer, 2022, 127(8): 1507-1514. DOI: 10.1038/s41416-022-01923-2.
17.Ren F, Shang Q, Zhao S, et al. An exploration of the correlations between seven psychiatric disorders and the risks of breast cancer, breast benign tumors and breast inflammatory diseases: Mendelian randomization analyses[J]. Front Psychiatry, 2023, 14: 1179562. DOI: 10.3389/fpsyt.2023.1179562.
18.Hemani G, Zheng J, Elsworth B, et al. The MR-base platform supports systematic causal inference across the human phenome[J]. Elife, 2018, 7: e34408. DOI: 10.7554/eLife.34408.
19.Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression[J]. Int J Epidemiol, 2015, 44(2): 512-525. DOI: 10.1093/ije/dyv080.
20.Nazarzadeh M, Pinho-Gomes AC, Bidel Z, et al. Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study[J]. Eur Heart J, 2020, 41(40): 3913-3920. DOI: 10.1093/eurheartj/ehaa070.
21.Cui Y, Lu W, Shao T, et al. Severe mental illness and the risk of breast cancer: a two-sample, two-step multivariable Mendelian randomization study[J]. PLoS One, 2023, 18(9): e0291006. DOI: 10.1371/journal.pone.0291006.
22.Li DJ, Tsai SJ, Chen TJ, et al. Exposure to psychotropic drugs and breast cancer risk in patients with bipolar disorder and major depressive disorder: a nested case-control study[J]. Eur Arch Psychiatry Clin Neurosci, 2024. DOI: 10.1007/s00406-024-01798-9.
23.Lin GM, Chen YJ, Kuo DJ, et al. Cancer incidence in patients with schizophrenia or bipolar disorder: a nationwide population-based study in Taiwan, 1997-2009[J]. Schizophr Bull, 2013, 39(2): 407-416. DOI: 10.1093/schbul/sbr162.
24.Han B, Aung TW, Volkow ND, et al. Tobacco use, nicotine dependence, and cessation methods in US adults with psychosis[J]. JAMA Netw Open, 2023, 6(3): e234995. DOI: 10.1001/jamanetworkopen.2023.4995.
25.Afzal M, Siddiqi N, Ahmad B, et al. Prevalence of overweight and obesity in people with severe mental illness: systematic review and Meta-analysis[J]. Front Endocrinol (Lausanne), 2021, 12: 769309. DOI: 10.3389/fendo.2021.769309.
26.Taipale H, Solmi M, Lähteenvuo M, et al. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland[J]. Lancet Psychiatry, 2021, 8(10): 883-891. DOI: 10.1016/S2215-0366(21)00241-8.
27.Lindekilde N, Scheuer SH, Rutters F, et al. Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with Meta-analysis of 245 observational studies from 32 systematic reviews[J]. Diabetologia, 2022, 65(3): 440-456. DOI: 10.1007/s00125-021-05609-x.
28.Peckham E, Lorimer B, Spanakis P, et al. Health-risk behaviours among people with severe mental ill health: understanding modifiable risk in the Closing the Gap Health Study[J]. Br J Psychiatry, 2023, 222(4): 160-166. DOI: 10.1192/bjp.2022.143.
29.Ryan JE, Veliz P, McCabe SE, et al. Association of early onset of cannabis, cigarette, other drug use and schizophrenia or psychosis[J]. Schizophr Res, 2020, 215: 482-484. DOI: 10.1016/j.schres.2019.10.002.
30.Adams JB. Human breast cancer: concerted role of diet, prolactin and adrenal C19-delta 5-steroids in tumorigenesis[J]. Int J Cancer, 1992, 50(6): 854-858. DOI: 10.1002/ijc.2910500603.
31.Starek-Świechowicz B, Budziszewska B, Starek A. Endogenous estrogens-breast cancer and chemoprevention[J]. Pharmacol Rep, 2021, 73(6): 1497-1512. DOI: 10.1007/s43440-021-00317-0.
32.Wang YH, Li JQ, Shi JF, et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and Meta-analysis of cohort studies[J]. Mol Psychiatry, 2020, 25(7): 1487-1499. DOI: 10.1038/s41380-019-0595-x.
33.Liu HM, Ma LL, Li C, et al. The molecular mechanism of chronic stress affecting the occurrence and development of breast cancer and potential drug therapy[J]. Transl Oncol, 2022, 15(1): 101281. DOI: 10.1016/j.tranon.2021.101281.